Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.
P/B ratio for Marksans Pharma Limited (MARKSANS.NS)
P/B ratio as of 2023: 3.47
According to Marksans Pharma Limited's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.47. At the end of 2022 the company had a P/B ratio of 1.68.
P/B ratio history for Marksans Pharma Limited from 2004 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 3.47 |
| 2022 | 1.68 |
| 2021 | 1.55 |
| 2020 | 2.31 |
| 2019 | 0.89 |
| 2018 | 1.96 |
| 2017 | 2.94 |
| 2016 | 4.34 |
| 2015 | 4.17 |
| 2014 | 6.67 |
| 2013 | 6.48 |
| 2012 | 1.74 |
| 2011 | -0.36 |
| 2010 | 0.74 |
| 2009 | 1.12 |
| 2008 | 0.99 |
| 2007 | 4.66 |
| 2006 | 1.42 |
| 2005 | 6.87 |
| 2004 | 8.85 |